Jungsun Yoo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jungsun Yoo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Chanho Park
Department of Biological Sciences College of Information and Biotechnology Ulsan National Institute of Science and Technology 44919 Ulsan Republic of Korea
16 shared publications - Chu-Sook Kim
Department of Biological Sciences College of Information and Biotechnology Ulsan National Institute of Science and Technology 44919 Ulsan Republic of Korea
16 shared publications - Hyun-Woo Rhee
Department of Chemistry, Seoul National University, Seoul, Republic of Korea
16 shared publications - Jiseon Shin
Ulsan National Institute of Science and Technology 1 Department of Biological Sciences, College of Information and Biotechnology Ulsan, Republic of Korea
16 shared publications - Jiyoung Park
Department of Biological Sciences, College of Information and Biotechnology, Ulsan National Institute of Science and Technology, Ulsan, Republic of Korea
16 shared publications - Min Kim
Ulsan National Institute of Science and Technology 1 Department of Biological Sciences, College of Information and Biotechnology Ulsan, Republic of Korea
16 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
List of primary and secondary antibodies used for immunoblotting, immunofluorescence, and immunohistochemistry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
List of primary and secondary antibodies used for immunoblotting, immunofluorescence, and immunohistochemistry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Endotrophin (ETP) is a cleavage fragment of collagen VI α3 (COL6A3) that functions as a potent fibrotic and protumorigenic factor. ETP is a diagnostic and prognostic biomarker in hepatocellular carcinoma (HCC), continuously increasing throughout tumor development and promoting HCC progression. Elucidation of the underlying molecular mechanisms by which ETP exerts protumorigenic effects in the liver could uncover potential therapeutic strategies. Using peroxidase-catalyzed proximity labeling, we identified CD44 as an ETP receptor. ETP binding to CD44 activated STAT3 signaling, promoting epithelial–mesenchymal transition (EMT), proliferation, and sorafenib resistance. Hepatic stellate cell–derived ETP targeted pericentral CD44+ tumor cells, inducing COL6A3 expression and sustaining ETP production via a STAT3-dependent feedback loop. Disruption of this axis by CD44 knockout, STAT3 inhibition, or CD44 binding–deficient ETP mutants suppressed malignant phenotypes in vitro. In metabolic dysfunction–associated HCC induced by diethylnitrosamine plus high-fat diet, dual knockout of Col6a3 and Cd44 in mice markedly reduced tumor burden, restored sorafenib sensitivity, and attenuated EMT, fibrosis, and steatotic–fibrotic niche formation. These findings establish the ETP–CD44–STAT3 axis as a driver of tumor–stroma cross-talk linking fibroinflammation to malignancy, highlighting it as a therapeutic target in obesity-associated liver cancer.Significance:CD44 serves as a receptor for endotrophin to activate STAT3 and drive EMT, fibroinflammatory niche formation, and malignant progression in metabolic dysfunction-associated hepatocellular carcinoma, suggesting this axis could represent a therapeutic target.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Endotrophin (ETP) is a cleavage fragment of collagen VI α3 (COL6A3) that functions as a potent fibrotic and protumorigenic factor. ETP is a diagnostic and prognostic biomarker in hepatocellular carcinoma (HCC), continuously increasing throughout tumor development and promoting HCC progression. Elucidation of the underlying molecular mechanisms by which ETP exerts protumorigenic effects in the liver could uncover potential therapeutic strategies. Using peroxidase-catalyzed proximity labeling, we identified CD44 as an ETP receptor. ETP binding to CD44 activated STAT3 signaling, promoting epithelial–mesenchymal transition (EMT), proliferation, and sorafenib resistance. Hepatic stellate cell–derived ETP targeted pericentral CD44+ tumor cells, inducing COL6A3 expression and sustaining ETP production via a STAT3-dependent feedback loop. Disruption of this axis by CD44 knockout, STAT3 inhibition, or CD44 binding–deficient ETP mutants suppressed malignant phenotypes in vitro. In metabolic dysfunction–associated HCC induced by diethylnitrosamine plus high-fat diet, dual knockout of Col6a3 and Cd44 in mice markedly reduced tumor burden, restored sorafenib sensitivity, and attenuated EMT, fibrosis, and steatotic–fibrotic niche formation. These findings establish the ETP–CD44–STAT3 axis as a driver of tumor–stroma cross-talk linking fibroinflammation to malignancy, highlighting it as a therapeutic target in obesity-associated liver cancer.Significance:CD44 serves as a receptor for endotrophin to activate STAT3 and drive EMT, fibroinflammatory niche formation, and malignant progression in metabolic dysfunction-associated hepatocellular carcinoma, suggesting this axis could represent a therapeutic target.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
APEX2-based proximity labeling strategy identifying CD44 as a binding partner of COL6A3-derived endotrophin, including schematic overview, proteomic screening, and validation of the CD44–ETP interaction
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
APEX2-based proximity labeling strategy identifying CD44 as a binding partner of COL6A3-derived endotrophin, including schematic overview, proteomic screening, and validation of the CD44–ETP interaction
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
RT-qPCR primer sequences for human and mouse genes related to fibrosis, EMT, immune response, and angiogenesis
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
RT-qPCR primer sequences for human and mouse genes related to fibrosis, EMT, immune response, and angiogenesis
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Comparative analysis of immune cell infiltration and vascular features between control and COL6A3/CD44 double-knockout tumors
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Comparative analysis of immune cell infiltration and vascular features between control and COL6A3/CD44 double-knockout tumors
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Enhanced MMP expression and protease activity during HCC–HSC interaction promoting endotrophin cleavage, assessed using an ETP cleavage biosensor system
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Enhanced MMP expression and protease activity during HCC–HSC interaction promoting endotrophin cleavage, assessed using an ETP cleavage biosensor system
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Primer sequences and cloning information for PCR amplification of the human COL6A3 promoter
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Primer sequences and cloning information for PCR amplification of the human COL6A3 promoter
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Basal STAT3 activation status in liver cancer cells according to COL6A3 and CD44 expression levels
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Basal STAT3 activation status in liver cancer cells according to COL6A3 and CD44 expression levels
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Primer sequences used for mouse genotyping of Col6a3 and Cd44 alleles
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Primer sequences used for mouse genotyping of Col6a3 and Cd44 alleles
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Identification of hepatic stellate cells as the primary source of COL6A3-derived endotrophin in DEN+HFD-induced hepatocellular carcinoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Endotrophin- and CD44-Mediated Heterotypic Signaling Mediates Tumor–Stroma Cross-talk and Facilitates Malignant Progression in Hepatocellular Carcinoma
Identification of hepatic stellate cells as the primary source of COL6A3-derived endotrophin in DEN+HFD-induced hepatocellular carcinoma